NZ529029A - Microprojection array having a beneficial agent containing coating - Google Patents
Microprojection array having a beneficial agent containing coatingInfo
- Publication number
- NZ529029A NZ529029A NZ529029A NZ52902902A NZ529029A NZ 529029 A NZ529029 A NZ 529029A NZ 529029 A NZ529029 A NZ 529029A NZ 52902902 A NZ52902902 A NZ 52902902A NZ 529029 A NZ529029 A NZ 529029A
- Authority
- NZ
- New Zealand
- Prior art keywords
- coating
- microprojections
- beneficial agent
- biocompatible carrier
- agent
- Prior art date
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 170
- 239000011248 coating agent Substances 0.000 title claims abstract description 145
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 117
- 230000009286 beneficial effect Effects 0.000 title claims abstract description 81
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 210000001124 body fluid Anatomy 0.000 claims abstract description 6
- 239000010839 body fluid Substances 0.000 claims abstract description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 15
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 15
- 229960005486 vaccine Drugs 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 210000002615 epidermis Anatomy 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 239000003975 dentin desensitizing agent Substances 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229940043138 pentosan polysulfate Drugs 0.000 claims description 4
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 3
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 108010064470 polyaspartate Proteins 0.000 claims description 3
- 229920002643 polyglutamic acid Polymers 0.000 claims description 3
- 229920002704 polyhistidine Polymers 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229960000633 dextran sulfate Drugs 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 59
- 239000003814 drug Substances 0.000 description 40
- 229940079593 drug Drugs 0.000 description 35
- 239000007787 solid Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 239000007788 liquid Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 13
- 230000004907 flux Effects 0.000 description 12
- 102000009027 Albumins Human genes 0.000 description 10
- 108010088751 Albumins Proteins 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 8
- 229930105110 Cyclosporin A Natural products 0.000 description 7
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 7
- 108010036949 Cyclosporine Proteins 0.000 description 7
- 238000003491 array Methods 0.000 description 7
- 229960001265 ciclosporin Drugs 0.000 description 7
- 239000011324 bead Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000013566 allergen Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005530 etching Methods 0.000 description 5
- 230000037317 transdermal delivery Effects 0.000 description 5
- 238000013271 transdermal drug delivery Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000008199 coating composition Substances 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000004080 punching Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- -1 vaccine Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 230000009056 active transport Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ZDRRIRUAESZNIH-BZGUUIOASA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZDRRIRUAESZNIH-BZGUUIOASA-N 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 108010091893 Cosyntropin Proteins 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010057021 Menotropins Proteins 0.000 description 1
- 229940124939 Pox vaccine Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 108010047196 Urofollitropin Proteins 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- ZOEFCCMDUURGSE-SQKVDDBVSA-N cosyntropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-SQKVDDBVSA-N 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940042470 lyme disease vaccine Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940095293 mumps vaccine Drugs 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013573 pollen allergen Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004371 urofollitropin Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940021648 varicella vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/20—Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ538043A NZ538043A (en) | 2001-04-24 | 2002-04-20 | Composition having a beneficial agent for forming a solid coating on microprojections array |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28557601P | 2001-04-20 | 2001-04-20 | |
| PCT/US2002/012730 WO2002085447A2 (en) | 2001-04-20 | 2002-04-20 | Microprojection array having a beneficial agent containing coating |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ529029A true NZ529029A (en) | 2005-07-29 |
Family
ID=23094848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ529029A NZ529029A (en) | 2001-04-20 | 2002-04-20 | Microprojection array having a beneficial agent containing coating |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7963935B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1392389B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2004528900A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20040020889A (cg-RX-API-DMAC7.html) |
| CN (2) | CN100349632C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE444773T1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0209046A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2444883A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60233939D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2333849T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL158480A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA03009603A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20034684L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ529029A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002085447A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200309006B (cg-RX-API-DMAC7.html) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6219574B1 (en) * | 1996-06-18 | 2001-04-17 | Alza Corporation | Device and method for enchancing transdermal sampling |
| US6918901B1 (en) * | 1997-12-10 | 2005-07-19 | Felix Theeuwes | Device and method for enhancing transdermal agent flux |
| KR20030068137A (ko) * | 2000-10-13 | 2003-08-19 | 알자 코포레이션 | 충격 어플리케이터용 미세 돌기 부재 리테이너 |
| US7419481B2 (en) * | 2000-10-13 | 2008-09-02 | Alza Corporation | Apparatus and method for piercing skin with microprotrusions |
| RU2275871C2 (ru) * | 2000-10-13 | 2006-05-10 | Алза Корпорейшн | Устройство и способ для прокалывания кожи микровыступами |
| US6821281B2 (en) | 2000-10-16 | 2004-11-23 | The Procter & Gamble Company | Microstructures for treating and conditioning skin |
| US7828827B2 (en) | 2002-05-24 | 2010-11-09 | Corium International, Inc. | Method of exfoliation of skin using closely-packed microstructures |
| US7131987B2 (en) | 2000-10-16 | 2006-11-07 | Corium International, Inc. | Microstructures and method for treating and conditioning skin which cause less irritation during exfoliation |
| EP2085109A3 (en) * | 2000-10-26 | 2009-09-02 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
| US6855372B2 (en) * | 2001-03-16 | 2005-02-15 | Alza Corporation | Method and apparatus for coating skin piercing microprojections |
| US20020193729A1 (en) * | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
| EP1485317A2 (en) * | 2001-11-30 | 2004-12-15 | Alza Corporation | Methods and apparatuses for forming microprojection arrays |
| DE60223844T2 (de) * | 2001-12-20 | 2008-08-28 | Alza Corp., Mountain View | Mikrovorsprünge zum durchstechen der haut mit stechtiefensteuerung |
| GB0201736D0 (en) * | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | DNA dosage forms |
| AR040819A1 (es) * | 2002-08-08 | 2005-04-20 | Alza Corp | Dispositivo de administracion transdermica de vacuna que tiene microproyecciones revestidas |
| US20040115167A1 (en) * | 2002-09-30 | 2004-06-17 | Michel Cormier | Drug delivery device and method having coated microprojections incorporating vasoconstrictors |
| AR042815A1 (es) * | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| US7578954B2 (en) | 2003-02-24 | 2009-08-25 | Corium International, Inc. | Method for manufacturing microstructures having multiple microelements with through-holes |
| KR20060038407A (ko) | 2003-06-30 | 2006-05-03 | 알자 코포레이션 | 비휘발성 반대이온을 포함하는 코팅된 미세돌출부용 제제 |
| US20050123507A1 (en) * | 2003-06-30 | 2005-06-09 | Mahmoud Ameri | Formulations for coated microprojections having controlled solubility |
| CA2530520A1 (en) * | 2003-06-30 | 2005-01-20 | Alza Corporation | Method for coating skin piercing microprojections |
| CA2530954A1 (en) * | 2003-07-02 | 2005-01-13 | Alza Corporation | Microprojection array immunization patch and method |
| WO2005016441A1 (en) * | 2003-08-04 | 2005-02-24 | Alza Corporation | Method and device for enhancing transdermal agent flux |
| US8524272B2 (en) * | 2003-08-15 | 2013-09-03 | Mylan Technologies, Inc. | Transdermal patch incorporating active agent migration barrier layer |
| CA2536249A1 (en) * | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
| EP1678293A2 (en) * | 2003-10-23 | 2006-07-12 | Alza Corporation | Compositions of stabilized dna for coating microprojections |
| WO2005042054A2 (en) * | 2003-10-24 | 2005-05-12 | Alza Corporation | Pretreatment method and system for enhancing transdermal drug delivery |
| KR20060120156A (ko) * | 2003-10-28 | 2006-11-24 | 알자 코포레이션 | 담배의 이용빈도를 감소시키기 위한 방법 및 장치 |
| BRPI0416132A (pt) * | 2003-10-31 | 2007-01-02 | Alza Corp | sistema e método para liberação de vacina transdérmica |
| BRPI0415629A (pt) | 2003-10-31 | 2006-12-12 | Alza Corp | aplicador auto-atuador para conjunto de microprojeções |
| GB0402131D0 (en) | 2004-01-30 | 2004-03-03 | Isis Innovation | Delivery method |
| JP5085317B2 (ja) | 2004-03-24 | 2012-11-28 | コリウム インターナショナル， インコーポレイテッド | 経皮送達デバイス |
| MXPA06011429A (es) * | 2004-04-01 | 2007-04-25 | Johnson & Johnson | Aparato y metodo para el suministro transdermico de la vacuna contra la influenza. |
| AU2005235075A1 (en) * | 2004-04-13 | 2005-11-03 | Alza Corporation | Apparatus and method for transdermal delivery of fentany-based agents |
| US20050271684A1 (en) * | 2004-04-13 | 2005-12-08 | Trautman Joseph C | Apparatus and method for transdermal delivery of multiple vaccines |
| US7556821B2 (en) * | 2004-05-13 | 2009-07-07 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
| CN100566669C (zh) * | 2004-05-13 | 2009-12-09 | 阿尔扎公司 | 甲状旁腺激素药物的透皮释放装置 |
| US7591806B2 (en) * | 2004-05-18 | 2009-09-22 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
| US20060030811A1 (en) * | 2004-08-03 | 2006-02-09 | Wong Patrick S | Method and device for enhancing transdermal agent flux |
| TW200626196A (en) * | 2004-09-08 | 2006-08-01 | Alza Corp | Microprojection array with improved skin adhesion and compliance |
| KR101224257B1 (ko) * | 2004-11-18 | 2013-01-18 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 마이크로니들 어레이를 코팅하기 위한 마스킹 방법 |
| WO2006055844A2 (en) | 2004-11-18 | 2006-05-26 | 3M Innovative Properties Company | Method of contact coating a microneedle array |
| US8267889B2 (en) | 2004-11-18 | 2012-09-18 | 3M Innovative Properties Company | Low-profile microneedle array applicator |
| US8057842B2 (en) | 2004-11-18 | 2011-11-15 | 3M Innovative Properties Company | Method of contact coating a microneedle array |
| ATE483493T1 (de) * | 2004-12-10 | 2010-10-15 | 3M Innovative Properties Co | Medizinische vorrichtung |
| CN101160117A (zh) * | 2005-02-16 | 2008-04-09 | 阿尔扎公司 | 依泊汀-基药物的透皮释放装置和方法 |
| US8048017B2 (en) * | 2005-05-18 | 2011-11-01 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
| US8043250B2 (en) * | 2005-05-18 | 2011-10-25 | Nanomed Devices, Inc. | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
| WO2006138719A2 (en) | 2005-06-17 | 2006-12-28 | Georgia Tech Research Corporation | Coated microstructures and method of manufacture thereof |
| WO2007002523A2 (en) | 2005-06-24 | 2007-01-04 | 3M Innovative Properties Company | Collapsible patch with microneedle array |
| US20080214952A1 (en) * | 2005-07-11 | 2008-09-04 | Jose Mir | Replaceable Cartridge for Allergy Testing System |
| CN101227940A (zh) * | 2005-07-25 | 2008-07-23 | 纳米技术维多利亚有限公司 | 微阵列装置 |
| JP5006196B2 (ja) | 2005-08-01 | 2012-08-22 | 久光製薬株式会社 | 経皮または経粘膜投与のためのアジュバントおよび製剤 |
| EP1924364A1 (en) * | 2005-09-12 | 2008-05-28 | Alza Corporation | Coatable transdermal delivery microprojection assembly |
| WO2007061964A1 (en) * | 2005-11-18 | 2007-05-31 | 3M Innovative Properties Company | Methods for coating microneedles |
| US7618429B2 (en) * | 2005-12-22 | 2009-11-17 | Spamedica International Srl | Skin rejuvination resurfacing method |
| WO2007084247A2 (en) * | 2005-12-28 | 2007-07-26 | Alza Corporation | Stable therapeutic formulations |
| ATE532553T1 (de) | 2006-02-10 | 2011-11-15 | Hisamitsu Pharmaceutical Co | Transdermales arzneiverabreichungsgerät mit mikronadeln |
| CA2680690A1 (en) * | 2006-03-15 | 2007-09-20 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia |
| US20070224252A1 (en) * | 2006-03-27 | 2007-09-27 | Trautman Joseph C | Microprojections with capillary control features and method |
| JP5049268B2 (ja) | 2006-04-07 | 2012-10-17 | 久光製薬株式会社 | マイクロニードルデバイスおよびマイクロニードル付き経皮薬物投与装置 |
| US9119945B2 (en) | 2006-04-20 | 2015-09-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
| WO2007127815A2 (en) * | 2006-04-25 | 2007-11-08 | Alza Corporation | Microprojection array application with multilayered microprojection member for high drug loading |
| US20070293816A1 (en) * | 2006-04-25 | 2007-12-20 | Alza Corporation | Microprojection Array Application with Grouped Microprojections for High Drug Loading |
| US20100100005A1 (en) * | 2006-07-11 | 2010-04-22 | Infotonics Technology Center, Inc. | Minimally invasive allergy testing system with coated allergens |
| US20090182306A1 (en) * | 2006-07-21 | 2009-07-16 | Georgia Tech Research Corporation | Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal |
| WO2008011625A2 (en) * | 2006-07-21 | 2008-01-24 | Georgia Tech Researh Corporation | Microneedle devices and methods of drug delivery or fluid withdrawal |
| ES2394525T3 (es) | 2006-09-27 | 2013-02-01 | Asahi Kasei Pharma Corporation | Calcitoninas para la prevención de la aparición de la distrofia simpática refleja tras un accidente cerebrovascular |
| US10525246B2 (en) | 2006-12-22 | 2020-01-07 | Nanomed Skincare, Inc. | Microdevice and method for transdermal delivery and sampling of active substances |
| US20080214987A1 (en) * | 2006-12-22 | 2008-09-04 | Nanomed Devices, Inc. | Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances |
| WO2008091602A2 (en) | 2007-01-22 | 2008-07-31 | Corium International, Inc. | Applicators for microneedle arrays |
| US20100047327A1 (en) * | 2007-01-31 | 2010-02-25 | Tetsuji Kuwahara | Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same |
| ES2473620T3 (es) | 2007-02-06 | 2014-07-07 | Hisamitsu Pharmaceutical Co., Inc. | Dispositivo de microagujas para el diagnóstico de una alergia |
| WO2008115599A1 (en) * | 2007-03-21 | 2008-09-25 | Alza Corporation | Apparatus and method for transdermal delivery of a 5-hydroxytrytamine antagonist |
| AU2008241470B2 (en) | 2007-04-16 | 2013-11-07 | Corium Pharma Solutions, Inc. | Solvent-cast microneedle arrays containing active |
| WO2009048607A1 (en) | 2007-10-10 | 2009-04-16 | Corium International, Inc. | Vaccine delivery via microneedle arrays |
| US20090137945A1 (en) * | 2007-11-28 | 2009-05-28 | Claire Marquez | Electro Collagen Induction Therapy Device |
| US9220678B2 (en) * | 2007-12-24 | 2015-12-29 | The University Of Queensland | Coating method |
| WO2009094394A1 (en) * | 2008-01-23 | 2009-07-30 | Georgia Tech Research Corporation | Microneedle devices and methods of drug delivery or fluid withdrawal |
| WO2009097660A1 (en) | 2008-02-07 | 2009-08-13 | The University Of Queensland | Patch production |
| JP5584202B2 (ja) | 2008-05-21 | 2014-09-03 | セラジェクト， インコーポレイテッド | 固溶体穿孔器パッチの製造方法及びその使用 |
| AU2009250341A1 (en) | 2008-05-23 | 2009-11-26 | The University Of Queensland | Analyte detection using a needle projection patch |
| US7943187B2 (en) * | 2008-05-23 | 2011-05-17 | Bakr Rabie | Paeoniflorin preparations and uses thereof for fat reduction |
| JP2012504034A (ja) * | 2008-10-02 | 2012-02-16 | ヌリ−エム ウェルネス カンパニー リミテッド | 送風によるソリッドマイクロ構造体の製造方法及びこれから製造されたソリッドマイクロ構造体 |
| US8734697B2 (en) | 2008-12-22 | 2014-05-27 | The University Of Queensland | Patch production |
| KR101634836B1 (ko) | 2008-12-26 | 2016-06-29 | 히사미쓰 세이야꾸 가부시키가이샤 | 마이크로 니들 디바이스 |
| US8062568B2 (en) * | 2009-08-27 | 2011-11-22 | Korea University Research And Business Foundation | Nano pattern writer |
| WO2011140274A2 (en) | 2010-05-04 | 2011-11-10 | Corium International, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
| US9943673B2 (en) | 2010-07-14 | 2018-04-17 | Vaxxas Pty Limited | Patch applying apparatus |
| EP2679242B1 (en) | 2011-02-25 | 2020-09-09 | Hisamitsu Pharmaceutical Co., Inc. | Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing same |
| US20120222979A1 (en) | 2011-03-04 | 2012-09-06 | Elwha LLC, a limited liability company of the State of Delaware | Glassy compositions |
| EP3881781B1 (en) * | 2011-10-12 | 2023-03-29 | Vaxxas Pty Limited | Delivery device |
| KR101931845B1 (ko) | 2011-10-20 | 2018-12-21 | 코스메드 파마소티컬 씨오 쩜 엘티디 | 마이크로니들 용착법 |
| US9675675B2 (en) | 2011-11-30 | 2017-06-13 | 3M Innovative Properties Company | Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same |
| JP2013153959A (ja) * | 2012-01-30 | 2013-08-15 | Toppan Printing Co Ltd | 針状体の構造 |
| US10980865B2 (en) | 2012-08-10 | 2021-04-20 | Aquavit Pharmaceuticals, Inc. | Direct application system and method for the delivery of bioactive compositions and formulations |
| KR102265808B1 (ko) | 2012-12-21 | 2021-06-16 | 코리움, 인크. | 치료제의 전달을 위한 마이크로어레이 및 그것의 사용방법 |
| EP2974768A4 (en) | 2013-03-12 | 2017-05-17 | Takeda Pharmaceutical Company Limited | Micro-needle patch |
| EP2968887B1 (en) | 2013-03-12 | 2022-05-04 | Corium, Inc. | Microprojection applicators |
| CN105246458B (zh) | 2013-03-15 | 2020-09-15 | 考里安公司 | 用于治疗剂递送的微阵列及其使用方法 |
| EP4194028A1 (en) | 2013-03-15 | 2023-06-14 | Corium Pharma Solutions, Inc. | Multiple impact microprojection applicators |
| JP2016512754A (ja) | 2013-03-15 | 2016-05-09 | コリウム インターナショナル， インコーポレイテッド | 治療剤の送達のためのマイクロアレイ、使用方法および製造方法 |
| EP2968116A1 (en) | 2013-03-15 | 2016-01-20 | Corium International, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
| WO2014201259A1 (en) * | 2013-06-12 | 2014-12-18 | The Board Of Regents For Oklahoma State University | Fluttering ear tag for bovine vaccination |
| JP6114401B2 (ja) | 2013-10-31 | 2017-04-12 | 久光製薬株式会社 | アジュバント組成物、これを含むアジュバント製剤、及びキット |
| FI3122426T3 (fi) | 2014-03-28 | 2023-03-31 | Univ Duke | Rintasyövän hoitaminen käyttäen selektiivisiä estrogeenin reseptorin modulaattoreita |
| EP3188714A1 (en) | 2014-09-04 | 2017-07-12 | Corium International, Inc. | Microstructure array, methods of making, and methods of use |
| CA2975275C (en) | 2015-02-02 | 2023-08-29 | Vaxxas Pty Limited | Microprojection array applicator and method |
| RU2747228C2 (ru) | 2015-04-29 | 2021-04-29 | Радиус Фармасьютикалз, Инк. | Способы лечения рака |
| WO2017004067A1 (en) | 2015-06-29 | 2017-01-05 | Corium International, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
| WO2017045031A1 (en) | 2015-09-18 | 2017-03-23 | Vaxxas Pty Limited | Microprojection arrays with microprojections having large surface area profiles |
| EP3355981B1 (en) | 2015-09-28 | 2025-11-19 | Vaxxas Pty Limited | Microprojection arrays with enhanced skin penetrating properties and methods thereof |
| AU2016339033B2 (en) * | 2015-10-12 | 2021-04-08 | Reflow Medical, Inc. | Stents having protruding drug-delivery features and associated systems and methods |
| US9918932B2 (en) | 2016-02-19 | 2018-03-20 | Zosano Pharma Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines |
| JP2017164308A (ja) * | 2016-03-16 | 2017-09-21 | 凸版印刷株式会社 | 穿刺デバイス及びその製造方法 |
| KR20170115429A (ko) * | 2016-04-07 | 2017-10-17 | 랩앤피플주식회사 | 생체분해성 금속을 이용한 마이크로 니들 |
| JP7034425B2 (ja) | 2016-04-15 | 2022-03-14 | エーディーエムバイオサイエンス インコーポレイテッド | 核酸フィルムの製造方法及び核酸フィルムを用いた薬物注入装置 |
| CA3020333A1 (en) | 2016-04-18 | 2017-10-26 | Radius Health, Inc. | Formulations of abaloparatide, transdermal patches thereof, and uses thereof |
| LT3565542T (lt) | 2017-01-05 | 2024-07-10 | Radius Pharmaceuticals, Inc. | Polimorfinės rad1901-2hcl formos |
| WO2018176102A1 (en) | 2017-03-31 | 2018-10-04 | Vaxxas Pty Limited | Device and method for coating surfaces |
| CA3065371A1 (en) | 2017-06-13 | 2018-12-20 | Vaxxas Pty Limited | Quality control of substrate coatings |
| AU2018309562A1 (en) | 2017-08-04 | 2020-02-20 | Vaxxas Pty Limited | Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP) |
| US11660264B2 (en) | 2017-08-23 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
| CA3073442C (en) | 2017-08-23 | 2024-02-06 | Zosano Pharma Corporation | Method of rapidly achieving therapeutic concentrations of zolmitriptan for treatment of migraines and cluster headaches |
| KR102146704B1 (ko) * | 2018-04-13 | 2020-08-21 | 가천대학교 산학협력단 | 사이클로스포린 A (CsA) 경피 및 피내 약물전달용 마이크로구조체 |
| US11660265B2 (en) | 2018-06-28 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
| JP7473486B2 (ja) | 2018-07-04 | 2024-04-23 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｒａｄ１９０１－２ｈｃｌの多形形態 |
| KR20210127961A (ko) | 2019-02-12 | 2021-10-25 | 래디어스 파마슈티컬스, 인코포레이티드 | 방법 및 화합물 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE25637E (en) | 1964-09-08 | Means for vaccinating | ||
| US3136314A (en) | 1960-08-01 | 1964-06-09 | Kravitz Harvey | Vaccinating devices |
| US3556080A (en) * | 1968-04-08 | 1971-01-19 | Lincoln Lab Inc | Skin allergy testing device |
| US3964482A (en) | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
| US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
| BE795384A (fr) | 1972-02-14 | 1973-08-13 | Ici Ltd | Pansements |
| OA05448A (fr) | 1975-10-16 | 1981-03-31 | Manufrance Manufacture Francai | Dispositif vaccinateur multipénétrant. |
| FR2474856A1 (fr) | 1980-01-31 | 1981-08-07 | Merieux Inst | Dispositif scarificateur |
| US4473083A (en) * | 1981-12-14 | 1984-09-25 | Maganias Nicholas H | Device and method for allergy testing |
| JPS60193925A (ja) | 1984-03-13 | 1985-10-02 | Chemo Sero Therapeut Res Inst | 凍結乾燥製剤化ワクチン |
| KR970008118B1 (ko) | 1987-07-09 | 1997-05-21 | 엘테에스 로오만 테라피-지스테메 게엠베하 운트 콤파니 카게 | 피부 침투성 치료 시스템 |
| CA2016900A1 (en) | 1989-07-06 | 1991-01-06 | Ronald J. Filipski | Tines structure in clinical applicator |
| EP0429842B1 (en) * | 1989-10-27 | 1996-08-28 | Korea Research Institute Of Chemical Technology | Device for the transdermal administration of protein or peptide drug |
| US5279544A (en) | 1990-12-13 | 1994-01-18 | Sil Medics Ltd. | Transdermal or interdermal drug delivery devices |
| US5437656A (en) | 1991-02-27 | 1995-08-01 | Leonard Bloom | Method and device for inhibiting H.I.V. hepatitis B and other viruses and germs when using a needle, scalpel and other sharp instrument in a medical environment |
| DE4222380A1 (de) | 1992-07-08 | 1994-01-13 | Ernst Peter Prof Dr M Strecker | In den Körper eines Patienten perkutan implantierbare Endoprothese |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| DE4341444C2 (de) | 1993-12-04 | 1996-03-14 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung |
| US5457041A (en) * | 1994-03-25 | 1995-10-10 | Science Applications International Corporation | Needle array and method of introducing biological substances into living cells using the needle array |
| US6586006B2 (en) * | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| CZ297431B6 (cs) * | 1994-08-04 | 2006-12-13 | Quadrant Holdings Cambridge Limited | Prostredek obsahující dodávací systém pevné dávkypro prímou aplikaci v pevné forme a zpusob jeho výroby |
| ATE177325T1 (de) | 1994-12-09 | 1999-03-15 | Novartis Erfind Verwalt Gmbh | Transdermales system |
| JP3601102B2 (ja) | 1995-03-15 | 2004-12-15 | ブラザー工業株式会社 | インクジェット式印刷記録装置と印字システム |
| DE19514104C2 (de) | 1995-04-13 | 1997-05-28 | Behringwerke Ag | Beschichtung für in den Blutstrom oder in das Gewebe des menschlichen Körpers einbringbares Biomaterial |
| WO1996037256A1 (en) | 1995-05-22 | 1996-11-28 | Silicon Microdevices, Inc. | Micromechanical patch for enhancing the delivery of compounds through the skin |
| WO1996037155A1 (en) | 1995-05-22 | 1996-11-28 | Silicon Microdevices, Inc. | Micromechanical device and method for enhancing delivery of compounds through the skin |
| WO1997002047A1 (fr) | 1995-07-03 | 1997-01-23 | Koken Co., Ltd. | Preparations de genes |
| DE19525607A1 (de) | 1995-07-14 | 1997-01-16 | Boehringer Ingelheim Kg | Transcorneales Arzneimittelfreigabesystem |
| US6219574B1 (en) * | 1996-06-18 | 2001-04-17 | Alza Corporation | Device and method for enchancing transdermal sampling |
| ATE241405T1 (de) | 1996-07-03 | 2003-06-15 | Altea Therapeutics Corp | Mehrfache mechanische mikroperforierung von haut oder schleimhäuten |
| US5738728A (en) | 1996-07-26 | 1998-04-14 | Bio Dot, Inc. | Precision metered aerosol dispensing apparatus |
| US5916524A (en) | 1997-07-23 | 1999-06-29 | Bio-Dot, Inc. | Dispensing apparatus having improved dynamic range |
| US5741554A (en) | 1996-07-26 | 1998-04-21 | Bio Dot, Inc. | Method of dispensing a liquid reagent |
| US5743960A (en) | 1996-07-26 | 1998-04-28 | Bio-Dot, Inc. | Precision metered solenoid valve dispenser |
| WO1998011937A1 (en) | 1996-09-17 | 1998-03-26 | Deka Products Limited Partnership | System for delivery of drugs by transport |
| US6197013B1 (en) * | 1996-11-06 | 2001-03-06 | Setagon, Inc. | Method and apparatus for drug and gene delivery |
| WO1998028037A1 (en) | 1996-12-20 | 1998-07-02 | Alza Corporation | Device and method for enhancing transdermal agent flux |
| DE19654391A1 (de) | 1996-12-27 | 1998-07-02 | Basf Ag | Katalysator zur selektiven Herstellung von Propylen aus Propan |
| GB2334005B (en) | 1996-12-31 | 2001-02-07 | Shell Internat Res Maatschhapp | Spar platform with vertical slots |
| US20020009464A1 (en) * | 1997-07-03 | 2002-01-24 | Camilo Colaco | Modified glycosides, compositions comprised thereof and methods of use thereof |
| US6918901B1 (en) | 1997-12-10 | 2005-07-19 | Felix Theeuwes | Device and method for enhancing transdermal agent flux |
| EP1037686B1 (en) * | 1997-12-11 | 2005-08-17 | Alza Corporation | Device for enhancing transdermal agent flux |
| KR100557261B1 (ko) | 1997-12-11 | 2006-03-07 | 알자 코포레이션 | 경피성 작용제 유동률을 증진시키기 위한 장치 |
| CA2313458C (en) * | 1997-12-11 | 2007-04-17 | Alza Corporation | Device for enhancing transdermal agent flux |
| US6091975A (en) | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
| AU767122B2 (en) | 1998-06-10 | 2003-10-30 | Georgia Tech Research Corporation | Microneedle devices and methods of manufacture and use thereof |
| US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6532386B2 (en) * | 1998-08-31 | 2003-03-11 | Johnson & Johnson Consumer Companies, Inc. | Electrotransort device comprising blades |
| CA2352974A1 (en) | 1998-12-18 | 2000-06-22 | John H. Livingston | Insertion sets with micro-piercing members for use with medical devices and methods of using the same |
| EP1163024B1 (en) | 1999-01-28 | 2003-12-17 | Cyto Pulse Sciences, Inc. | Delivery of macromolecules into cells |
| US6884427B1 (en) | 1999-02-08 | 2005-04-26 | Aderans Research Institute, Inc. | Filamentary means for introducing agents into tissue of a living host |
| ATE244558T1 (de) | 1999-04-16 | 2003-07-15 | Novo Nordisk As | Trockene formbare arzneistoffformulierung |
| US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| EP1189660B1 (en) * | 1999-06-08 | 2006-05-03 | Altea Therapeutics Corporation | Apparatus for microporation of biological membranes using thin film tissue interface devices, and method therefor |
| US6379324B1 (en) | 1999-06-09 | 2002-04-30 | The Procter & Gamble Company | Intracutaneous microneedle array apparatus |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| US6312612B1 (en) * | 1999-06-09 | 2001-11-06 | The Procter & Gamble Company | Apparatus and method for manufacturing an intracutaneous microneedle array |
| US6623457B1 (en) * | 1999-09-22 | 2003-09-23 | Becton, Dickinson And Company | Method and apparatus for the transdermal administration of a substance |
| US6835184B1 (en) * | 1999-09-24 | 2004-12-28 | Becton, Dickinson And Company | Method and device for abrading skin |
| US20020095134A1 (en) | 1999-10-14 | 2002-07-18 | Pettis Ronald J. | Method for altering drug pharmacokinetics based on medical delivery platform |
| SE0000363L (sv) | 2000-02-04 | 2001-08-05 | Zoucas Kirurgkonsult Ab | Belagd medicinsk anordning |
| US6558361B1 (en) * | 2000-03-09 | 2003-05-06 | Nanopass Ltd. | Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems |
| US6565532B1 (en) | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
| US6537242B1 (en) | 2000-06-06 | 2003-03-25 | Becton, Dickinson And Company | Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance |
| US20050008683A1 (en) | 2000-06-29 | 2005-01-13 | Becton Dickinson And Company | Method for delivering interferons to the intradermal compartment |
| US6589202B1 (en) | 2000-06-29 | 2003-07-08 | Becton Dickinson And Company | Method and apparatus for transdermally sampling or administering a substance to a patient |
| US6440096B1 (en) | 2000-07-14 | 2002-08-27 | Becton, Dickinson And Co. | Microdevice and method of manufacturing a microdevice |
| GB0017999D0 (en) * | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
| RU2275871C2 (ru) | 2000-10-13 | 2006-05-10 | Алза Корпорейшн | Устройство и способ для прокалывания кожи микровыступами |
| HUP0303583A2 (en) | 2000-10-13 | 2004-01-28 | Alza Corp | Microblade array impact applicator |
| KR20030068137A (ko) | 2000-10-13 | 2003-08-19 | 알자 코포레이션 | 충격 어플리케이터용 미세 돌기 부재 리테이너 |
| EP2085109A3 (en) | 2000-10-26 | 2009-09-02 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
| GB0026957D0 (en) * | 2000-11-03 | 2000-12-20 | Eastman Kodak Co | Processing photographic materal |
| US6638246B1 (en) * | 2000-11-28 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device for delivery of a biologically active material to a lumen |
| US9302903B2 (en) | 2000-12-14 | 2016-04-05 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
| US6855372B2 (en) | 2001-03-16 | 2005-02-15 | Alza Corporation | Method and apparatus for coating skin piercing microprojections |
| US20020193729A1 (en) | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
| US6881203B2 (en) | 2001-09-05 | 2005-04-19 | 3M Innovative Properties Company | Microneedle arrays and methods of manufacturing the same |
| US20030135201A1 (en) | 2001-09-28 | 2003-07-17 | Gonnelli Robert R. | Microneedle with membrane |
| US6689100B2 (en) | 2001-10-05 | 2004-02-10 | Becton, Dickinson And Company | Microdevice and method of delivering or withdrawing a substance through the skin of an animal |
-
2002
- 2002-04-20 CN CNB028122518A patent/CN100349632C/zh not_active Expired - Fee Related
- 2002-04-20 ES ES02731464T patent/ES2333849T3/es not_active Expired - Lifetime
- 2002-04-20 KR KR10-2003-7013728A patent/KR20040020889A/ko not_active Ceased
- 2002-04-20 JP JP2002583020A patent/JP2004528900A/ja not_active Ceased
- 2002-04-20 BR BR0209046-5A patent/BR0209046A/pt not_active IP Right Cessation
- 2002-04-20 MX MXPA03009603A patent/MXPA03009603A/es unknown
- 2002-04-20 CN CNA2007101489918A patent/CN101129327A/zh active Pending
- 2002-04-20 WO PCT/US2002/012730 patent/WO2002085447A2/en not_active Ceased
- 2002-04-20 CA CA002444883A patent/CA2444883A1/en not_active Abandoned
- 2002-04-20 AT AT02731464T patent/ATE444773T1/de not_active IP Right Cessation
- 2002-04-20 EP EP02731464A patent/EP1392389B1/en not_active Expired - Lifetime
- 2002-04-20 NZ NZ529029A patent/NZ529029A/en unknown
- 2002-04-20 IL IL15848002A patent/IL158480A0/xx unknown
- 2002-04-20 DE DE60233939T patent/DE60233939D1/de not_active Expired - Lifetime
- 2002-04-20 US US10/127,108 patent/US7963935B2/en active Active
-
2003
- 2003-10-20 NO NO20034684A patent/NO20034684L/no not_active Application Discontinuation
- 2003-11-19 ZA ZA200309006A patent/ZA200309006B/en unknown
-
2011
- 2011-05-06 JP JP2011103757A patent/JP5611888B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BR0209046A (pt) | 2004-11-09 |
| ATE444773T1 (de) | 2009-10-15 |
| KR20040020889A (ko) | 2004-03-09 |
| CA2444883A1 (en) | 2002-10-31 |
| EP1392389B1 (en) | 2009-10-07 |
| EP1392389A2 (en) | 2004-03-03 |
| JP5611888B2 (ja) | 2014-10-22 |
| IL158480A0 (en) | 2004-05-12 |
| JP2011172968A (ja) | 2011-09-08 |
| WO2002085447A8 (en) | 2004-05-13 |
| JP2004528900A (ja) | 2004-09-24 |
| MXPA03009603A (es) | 2004-12-06 |
| ES2333849T3 (es) | 2010-03-02 |
| CN100349632C (zh) | 2007-11-21 |
| ZA200309006B (en) | 2005-02-21 |
| NO20034684D0 (no) | 2003-10-20 |
| WO2002085447A3 (en) | 2003-03-06 |
| DE60233939D1 (de) | 2009-11-19 |
| CN101129327A (zh) | 2008-02-27 |
| US7963935B2 (en) | 2011-06-21 |
| CN1541126A (zh) | 2004-10-27 |
| WO2002085447A2 (en) | 2002-10-31 |
| US20020177839A1 (en) | 2002-11-28 |
| NO20034684L (no) | 2003-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7963935B2 (en) | Microprojection array having a beneficial agent containing coating | |
| JP4875457B2 (ja) | 経皮的薬剤配達装置 | |
| US20080226687A1 (en) | Drug delivery and method having coated microprojections incorporating vasoconstrictors | |
| US20050106227A1 (en) | Delivery of polymer conjugates of therapeutic peptides and proteins via coated microprojections | |
| KR20050084493A (ko) | 구성 부재를 갖는 활성제 전달 장치 | |
| EP3251722B1 (en) | Microprojection array having a beneficial agent containing coating and method of forming the coating thereon | |
| JP2009507576A (ja) | 被膜可能な経皮送達微小突起アセンブリ | |
| AU2002303441B2 (en) | Microprojection array having a beneficial agent containing coating | |
| NZ538043A (en) | Composition having a beneficial agent for forming a solid coating on microprojections array | |
| AU2002303441A1 (en) | Microprojection array having a beneficial agent containing coating | |
| AU2010201135A1 (en) | Microprojection Array having a Beneficial Agent Containing Coating |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |